benzo[1,2,5]thiadiazole-4-sulfonic acid ethylamino-(4-ethyl-4,5-dihydro-pyrazol-1-yl)-methyleneamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻二唑类
• 英文名称: benzo[1,2,5]thiadiazole-4-sulfonic acid ethylamino-(4-ethyl-4,5-dihydro-pyrazol-1-yl)-methyleneamide
• 英文别名: N-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N',4-diethyl-3,4-dihydropyrazole-2-carboximidamide
• 化学式: C₁₄H₁₈N₆O₂S₂
• 分子量: 366.468
• InChiKey: AKCSTSNPSVKFMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  137
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N',4-diethyl-4,5-dihydro-1H-pyrazole-1-carboxamidine hydrochloride 、 苯并[1,2,5]噻二唑-4-磺酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以65%的产率得到benzo[1,2,5]thiadiazole-4-sulfonic acid ethylamino-(4-ethyl-4,5-dihydro-pyrazol-1-yl)-methyleneamide
  参考文献：
  名称：

  WO2008/34863

  摘要：

  公开号：

文献信息

• SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Van Loevezijn Arnold

  公开号：US20080311179A1

  公开（公告）日：2008-12-18

  This invention concerns compounds of the general formula (1). and derivatives thereof, which are antagonists of 5-HT 6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  本发明涉及通式（1）的化合物及其衍生物，它们是5-HT6受体拮抗剂，其中符号的含义如说明书所示。本发明还涉及制备这些化合物的方法，对于其合成有用的新型中间体，以及这些化合物和组合物的用途，特别是将它们用于向患者施用以达到治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤有关的疾病、脑积水、功能性肠道障碍、肠易激综合征、肥胖症和2型糖尿病等至少一种疾病或症状的治疗效果。
• Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists
  申请人：Solvay Pharmaceuticals B.V.

  公开号：US07728018B2

  公开（公告）日：2010-06-01

  This invention concerns compounds of the general formula (1): and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

  这项发明涉及一般式（1）的化合物及其衍生物，它们是5-HT6受体的拮抗剂，其中符号具有描述中所给出的含义。该发明还涉及制备这些化合物的方法，对于其合成有用的新中间体，以及这些化合物和组合物的用途，特别是将它们用于给患者治疗至少一种疾病或病状，包括帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安躁动、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓损伤或头部损伤相关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病。
• SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP2069310A2

  公开（公告）日：2009-06-17
• SULFONYLPYRAZOLINE-1-CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Abbott Healthcare Products B.V.

  公开号：EP2069310B1

  公开（公告）日：2011-12-14
• US7728018B2
  申请人：——

  公开号：US7728018B2

  公开（公告）日：2010-06-01